Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 571-580 of 982 for hematology

Edit search filters
  1. Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

    Rochester, MN

  2. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    Rochester, MN

  3. Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

    Scottsdale/Phoenix, AZ

  4. Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

    Rochester, MN

  5. Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

    Rochester, MN

  6. Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

    Rochester, MN

  7. Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Rochester, MN

  8. SC16LD6.5 in Recurrent Small Cell Lung Cancer

    Rochester, MN

  9. Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Study to Evaluate Gilteritinib vs. Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer